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ABSTRACT
[BH]-methotrexate binding at pH 5.0 and pH 7.2 by the cytosol of tumor tissues and the surrounding
normal areas of the gastrointestinal tract of patients suffering from colon or gastric cancer has been
used to identify In these cells the presence of a binder of methotrexate having low-affinity for this drug
in addition to the enzyme dihydrofolate reductase. Scatchard analysis of the [3H]- methotrexate binding
data by a colon tumor sample also reveals that there are two binders of this drug present In the cytosol
of these cells. The association constant (Kass) for one binder of methotrexate is = 5.6 x 10 M1 while
the Kass for the second binder is = 1.0 x 106 M1. The two binders do not differ very much in their
apparent molecular weight. Upon isoelectric focusing, the tumor cell cytosol resolves into 4 major
isoproteins each having the ability not only to bind [ H]- methotrexate but also reduce [H]pteroylglutamic acid to H]- tetrahydropteroylglutamic acid. This suggests that the two binders of
methotrexate may be the two forms of dihydrofolate reductase having different affinities for this
anticancer drug(JPMA 41:136, 1991).
INTRODUCTION
Dihydrofolate reductase (DHFE., EC. 1.5.1.3) plays a central role in the pathway of pyrimidine and
purine biosynthesis and, therefore, is a target enzyme in cancer chemotherapy. The anticancer drug
methotrexate (MTX) produces cytocidal effect by binding to DHFR and blocking its action. There have
been quite a few reports on the heterogeneity of the enzyme in terms of its binding to MDC in human
as well as murine leukemia cells 1-7 and mammalian liver8,9. Colorectal carcinoma is one of the most
common solid tumors in adults10. Since MTX as a single agent has never been considered to be of
much value in the management of advanced colorectal carcinoma, we attempted to find out whether
these cells contain another binder of MTX having low affinity for this drug and, therefore, would not
respond to MDC therapy.
MATERIALS AND METHODS
[3H] MTX with a specific activity 11.8 Ci/mmole and [3H] pteroylglutamic acid ([3H]PGA) with a
specific activity 34 Ci/mmole were purchased from Amersham/Searle. [3 H]MTX was purified by
chromatography on a Bio Gel P-30 column. NADPH, pteroylglutamic acid (PGA), MDC, pH
ampholytes (Ampholines), phenylmethylsulfonylfluoride (PMSF), Norit A Neutral charcoal, dextran
(molecular weight 10,000), bovine serum albumin, dextran blue, cytochrome C, horse raddish
peroxidase, ethanolamine were purchased from Sigma Chemical Company. Trasylol was obtained from
Mobay (New York). Preparation of tissue extracts Human tumor tissues (colon cancer) and the normal
tissues (surrounding the tumor), excised at the time of surgery were homogenized as described
previously11, but with a slight modification that the homogenates were prepared using 3 ml of 0.6 M
sodium citrate buffer, pH 7.2, for everygm of tissue. Since these tissue cells contain lysosomal

enzymes, trasylol (1000 KIU/1), PMSF (3.5 mg/i) and 0.02% sodium azide were included in the buffer
used for making homogenates. These homogenates were then centrifuged at 105,000 x g for 1 hr and
the cytosol obtained was analyzed for [3H]MTX binding at pH 5.0 and pH 7.2.
[3H]MTX binding studies
Binding of [3HJMTX by the tissue extracts was carried out by a procedure as described by Rothenberg
et al12. A total reaction volume of 0.5 ml in 0.06 M citrate, pH 4.8 or pH 7.4, containing 48 uM
NADPH, 5.8 mM 2-mercaptoethanol, 2.2 nM [3H]MTX, 0-22 nM unlabelled MDC and 50 ul cell
cytosol were incubated at room temperature for 30 minutes. The reactions were then stopped by the
addition of 0.4 ml of one percent Norit. A neutral charcoal in 0.5 percent dextran (molecular weight
10,000). After centrifugation, radioactivity in 0.5 ml of supernatant solution representing the enzyme
bound [3H]MTX was counted in an LS-3801 Spectrometer (Beckman Instruments, Palo Alto, CA)
using 5 ml of 3a70 scintillation fluor (Research Product International, USA). A blank containing all
constituents of the reaction mixture except the cytosol was run with each assay series to determine the
radioactivity not removed by charcoal in the absence of the cytosol preparation. This radioactivity was
subtracted from the experimental samples to determine the net counts per minute of bound [3H]MTX.
Preliminary experiments indicated that the coefficient of variation for separating bound and free MDC
by dextran-coated charcoal was between 2.1% and 3.8% when the binding activity was greater than 5%
of the total MDC.
Gel Column Chromatography
Sephadex G-75 was equilibrated with 0.05 M Tris HCI buffer, pH 7.4, containing 0.02% sodium azide
and packed in a column of size 0.7 cm x 50 cm. Half ml of colon tumor cytosol was applied to the
column and eluted at a flow rate of 4.8 mI/hr. Fractions in a volume of 0.5 ml were collected and
assayed for [3H]MDC binding at pH 7.2. Dextran blue, pure goat liver DHFR (Mr 20,000), horse
raddish peroxidase (Mr 40,000), cytochrome C (Mr 12,400) and3H2O were used as column markers.
Isoelectric Focusing
A colon tumor cytosol sample was analyzed by isoelectric focusing in a standard LKB 1 10-mI column
packed with 1% (W/V) ampholytes at a pH range of 3.5 10 in a zero to 50% sucrose gradient. The
sample (1 ml) was dialyzed against distilled water for 4 hrs to remove electrolytes prior to application
to the column. The dialyzed sample and the 75% of total ampholytes used were added to the solution
which was adjusted to contain 50% sucrose (“dense solution”). The remaining ampholytes (25%) were
mixed with “light solution” comprising of 5% sucrose. The electrode solution for the cathode (25 ml)
was 0.262 M. ethanolantine in 60% sucrose. The electrolyte solution for the anode (20 ml) was 0.173
M H3P04 prepared in distilled water. A fraction of this solution, enough to completely cover the
respective electrode was placed on top of the column. The column was run for 20 hrs at a maximum
power of 5W with the maximum voltage set at 1.6 KV. Two mgs. of pure hemoglobin was added
alongwith the sample as a marker for focusing. The column was eluted at a constant flow rate of 100
mI/hr and 0.9 ml fractions were collected. Every other fraction was dialyzed against 0.025 M potassium
phosphate buffer, pH 7.4 containing 0.025 M potassium chloride for 20 hrs to remove Ampholines and
then analyzed for [3H]MTX binding12 and for the reduction of [3H]PGA to [3H]-tetrahydro-PGAB.
RESULTS AND DISCUSSION

Figure 1 shows the binding of [3H]MTX at pH 5.0 and pH 7.2 by the colon tumor cytosol. At pH 5.0,
the maximum concentration of [3H]MTX bound was 0.73 nM as against 1.06 nM at pH 7.2 when the
total MDC concentration in the reaction was 24.2 nM. There was nearly 45% increase in the [3H]MTX
binding at pH 7.2. Since DHFR has been shown to have a higher affinity for MDC at acidic pH and a
lower affinity for the inhibitor at pH 7.214, increased MDC bindingat pH 7.2 as compared to at pH 5.0
suggests that in addition to DHFR there is an additional species of binding sites participating in the
reaction. Had there been only one form of the binder of this drug in these cells, the binding of
[3H]MTX at saturating concentration of total MDC in the reaction would have been the same at pH 5.0
and pH 7.2. A number of tumor tissues of gastrointestinal tract (GIT) and the surrounding normal areas
of GIT were analyzed for [3H]MTX binding at pH 5.0 and pH 7.2. As shown in Table,

it is evident that in most of the tissues examined, there is more binding of [3H]MTX at pFI 7.2 as
compared to pH 5.0. The difference in the total binding of [3H]MTX at the of drug bound to by one of
the colon tumor cytosol samples at increasing concentrations of the unlabelled MDC in the reactions.

Figure 2 shows that one of the binders of MDC had an association constant (Kass) = 5.6x 107 M-1,
while the other one had a Kass = 1.06x 106 M-1. These values are close to the two Kass values
reported for the two binders of MTX in human leukemia cells7. We could not separate the two binders
of MTX by gel-filtration chromatography because a single peak of [3H]MTX binding vas obtained
when colon tumor cytosol was applied to Sephadex G-75 column suggesting that the two binders may
not be differing much in their apparent molecular weight which appears to around 20,000 (Figure 3).

Previous multiple forms of DHFR in various types of cells, i.e., mouse fibroblasts, Escherichia coli,
L1210 and L5178 Y leukemia cells and goat liver cells, indicate that their molecular weights are either
identical16,17 or very closely similar3,4,9. In our study the major limitation in terms of separating and
characterizing these two binders of MDC has been the small amount of enzyme in these human tissues.
At the present moment we cannot be absolutely certain that the low affinity binder of MDC is in fact a
form of DHFR having weaker affinity for this antifolate. However, the isoelectric focusing profile of
the colon tumor cytosol (Figure.4)

shows 4 major isoproteins of dihydrofolate reductase activity with their pIs 7.3, 6.5, 5.7 and 4.7,
respectively. These isoproteins were obtained by analyzing the post-focusing fractions not only for
[3HJMTX binding at pH 7.2 but also for [3H]PGA reduction to [3H]-tetrahydro-PGA. The fact that the
four enzyme activity peaks co-elute exactly with the four [3H]MTX binding peaks suggests that the
low-affinity binder of [3H]MTX in colon tumor cells is probably another form of DHFR with altered
affinity for this anti-cancer drug. Since these cancer patients had never been treated with MTX, the
presence of a low affinity form of DHFR in their tumor cells indicates that insensitivity to MDC is an
intrinsic phenomenon in certain types of cells. Similar findings have been reported by Dedhar et al6 for
blast cells of acute myelogenous leukemia patients. MDC as a single agent has never been considered
effective in the management of colorectal or gastric carcinoma and that may have been due to the fact
that such cells might be containing a low affinity form of DI IFR. It has been reported by Jackson and
Harrap18 and White and Goldman19 that no more than 5% of the folate reductase activity is required to
generate sufficient tetrahydrofolate cofactors to maintain cell viability. Thus. if these cancer cells
contain a small amount of low affinity form of DHFR, it would be sufficient to maintain this de novo
DNA synthesis, even if all of the high affinity form of the enzyme has been inactivated by MTX. There
fore, in these cells unless very high doses of MTX are used, MDC in conventional or intermediate
doses would be unlikely to produce any good results. There have been quite a few reports of sequential
combination chemotherapy with MTX and 5-fluorouracil in the management of colorectal

cancer10,20,22, but in these cases the role of MDC is more in terms of enhancing the binding of 5fluorodeoxy-uridylate (FdUMP) to thymidylate synthetase rather than completely knocking off the
activity of DHFR23,24. In other words, MDC in these cells has a synergistic effect on the intracellular
utilization of 5-fluorouracil25,26. Thus, heterogeneity of MDC binding in the colon tumor provides us
with a plausible explanation about the ineffectiveness of MDC in the treatment of such tumors.
However, very high doses of MTX which have rarely been attempted in the management of colorectal
carcinoma, in theory at least, may be of value in obtaining the desired therapeutic responses.
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